deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT01937117

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Sponsor: Genentech, Inc.

Conditions Breast Cancer
Interventions Pertuzumab Positron emission tomography (PET) Trastuzumab
Updated 20 times since 2017 Last updated: Jun 23, 2025 Started: Jan 30, 2014 Primary completion: Mar 20, 2018 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01937117, this PHASE2 trial focuses on Breast Cancer and remains ongoing. Sponsored by Genentech, Inc., it has been updated 20 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~May 2018 · 7 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Nov 2022 · 11 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Mar 2024 · 13 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 15 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Feb 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  9. May 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Completed → Active Not Recruiting

  10. Sep 2018 — May 2019 [monthly]

    Completed PHASE2

  11. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE2

  12. May 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  13. Oct 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  14. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Translational Breast Cancer Research Consortium
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations